Tests of HIV vaccine using mRNA technology have begun | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 03, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 03, 2025
Tests of HIV vaccine using mRNA technology have begun

Health

Hindustan Times
28 January, 2022, 09:15 am
Last modified: 28 January, 2022, 09:22 am

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Tests of HIV vaccine using mRNA technology have begun

Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year

Hindustan Times
28 January, 2022, 09:15 am
Last modified: 28 January, 2022, 09:22 am
Tests of HIV vaccine using mRNA technology have begun
Tests of HIV vaccine using mRNA technology have begun

Testing in humans of an HIV vaccine that uses messenger RNA technology has begun, the biotech firm Moderna and the International AIDS Vaccine Initiative said Thursday.

This Phase 1 trial is being carried out in the United States among 56 healthy adults who are HIV negative.

Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS, which kills hundreds of thousands of people around the world each year.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

But hopes have been stirred with the success of mRNA technology, which allowed for the development of Covid-19 vaccines in record time, including one from Moderna.

The goal of the vaccine now being tested is to stimulate production of a kind of antibody called "broadly neutralizing antibodies," or bnAbs, which can act against the many variants of HIV that are circulating today.

The vaccine is supposed to teach B lymphocytes, which are part of the immune system, to generate these antibodies.

In this trial, participants are injected with an immunogen -- a substance that can trigger an immune response -- and then a booster immunogen later.

These substances will be delivered with mRNA technology.

"The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process," Moderna and the IAVI, a research organization, said in a statement.

"Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen," said David Diemert, a lead investigator at one of the four sites where the trial is being carried out, George Washington University in the US capital.

The immunogens used in this trial were developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the US National Institute of Allergy and Infectious Diseases and Moderna.

A first trial last year tested the first immunogen but without employing mRNA technology. It showed that the desired immune response was triggered in dozens of people taking part in the research.

The next step was to bring in Moderna with its new mRNA technique.

"Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing," the Moderna-IAVI statement said.

"The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," said Mark Feinberg, the CEO of IAVI.

 

 

Top News

Vaccine / AIDS / mRNA / Moderna

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Govt to pay 3-year high ACU bill of $2b next week
    Govt to pay 3-year high ACU bill of $2b next week
  • A file photo of the NBR Bhaban in Agargaon, Dhaka
    NBR officers gripped by fear as govt gets tough  
  • Bangladesh National Parliament. File Photo: Syed Zakir Hossain
    Has the time come for Bangladesh to embrace PR? 

MOST VIEWED

  • Govt lowers interest rates on savings instruments
    Govt lowers interest rates on savings instruments
  • File photo of Bangladesh Public Service Commission logo. Photo: Collected
    Repeat recommendations in 44th BCS spark vacancy fears
  • File photo of Chattogram Port/TBS
    Ctg port handles record 32.96 lakh containers in FY25, revenue hits Tk75,432 crore
  • Chief adviser’s Special Envoy for International Affairs and Adviser Lutfey Siddiqi
    Fake documents submission behind visa complications for Bangladeshis: Lutfey Siddiqi
  • Zakir Hossain. Photo: Collected
    Ctg customs commissioner suspended for joining NBR officials' 'complete shutdown'
  • Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue
    Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Features

Illustration: TBS

The buildup to July Uprising: From a simple anti-quota movement to a wildfire against autocracy

4h | Panorama
Illustration: TBS

Ulan Daspara: Remnants of a fishing village in Dhaka

2d | Panorama
Photo: Collected

Innovative storage accessories you’ll love

3d | Brands
Two competitors in this segment — one a flashy newcomer, the other a hybrid veteran — are going head-to-head: the GAC GS3 Emzoom and the Toyota CH-R. PHOTOS: Nafirul Haq (GAC Emzoom) and Akif Hamid (Toyota CH-R)

GAC Emzoom vs Toyota CH-R: The battle of tech vs trust

3d | Wheels

More Videos from TBS

Will Syria normalise relations with Israel?

Will Syria normalise relations with Israel?

3h | Others
Multinational companies' participation in the Israeli massacre in Gaza

Multinational companies' participation in the Israeli massacre in Gaza

4h | Others
July fighter Fahim doesn't want to be a burden.

July fighter Fahim doesn't want to be a burden.

4h | TBS Stories
The government has reduced the profit on savings certificates; what is its impact on the common man?

The government has reduced the profit on savings certificates; what is its impact on the common man?

6h | Podcast
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net